These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7287145)

  • 21. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involving the pharmaceutical and biotech communities in medication development for substance abuse.
    Gorodetzky CW; Grudzinskas C
    Pharmacol Ther; 2005 Oct; 108(1):109-18. PubMed ID: 16038981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Safety assessment of new products developed by the pharmaceutical industry].
    Claude JR
    Ann Pharm Fr; 2001 Sep; 59(5):324-30. PubMed ID: 11787426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Closing Remarks.
    Reed E
    Oncologist; 1996; 1(4):276-277. PubMed ID: 10388002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Are children getting the right drugs?].
    Bratlid D
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging science, emerging ethical issues: who should fund innate alloimmunity-suppressing drugs?
    Land WG; Gutmann T; Daar AS
    Acta Chir Belg; 2008; 108(1):73-82. PubMed ID: 18411578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No relaxation on drug safety and efficacy.
    Russell AS; Grace M
    World Health Forum; 1993; 14(1):31-3. PubMed ID: 8439367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Reform of Japan's NTP and its technical perspectives].
    Mori T
    Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trials in India: balancing economic opportunity with the public health context.
    Dandona L
    Natl Med J India; 2006; 19(2):57-9. PubMed ID: 16756189
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical trials: considerations for researchers and hospital administrators.
    Uecke O; Reszka R; Linke J; Steul M; Posselt T
    Health Care Manage Rev; 2008; 33(2):103-12. PubMed ID: 18360161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developing paediatric medicines: identifying the needs and recognizing the challenges.
    Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
    J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing the risks of therapeutic products: proceedings of a workshop.
    Kramer JM
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):619-28. PubMed ID: 15641121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What's next in translational medicine?
    Littman BH; Di Mario L; Plebani M; Marincola FM
    Clin Sci (Lond); 2007 Feb; 112(4):217-27. PubMed ID: 17223795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologicals: new horizons in pharmaceutical development.
    Oldham RK
    J Biol Response Mod; 1983; 2(3):199-206. PubMed ID: 6358418
    [No Abstract]   [Full Text] [Related]  

  • 39. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TDR collaboration with the pharmaceutical industry.
    Gutteridge WE
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S21-5. PubMed ID: 16730039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.